July 25, 2023 11:01 AM EDTUpdated 01:37 PM
Deals

Cor­rect­ed: Roche is not mov­ing for­ward with SQZ pro­gram, send­ing the biotech in­to strate­gic re­view

Lei Lei Wu

News Reporter

This sto­ry was cor­rect­ed to note that Roche has elect­ed not to take its op­tion on SQZ’s pro­gram. A pre­vi­ous ver­sion said that Roche and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times